FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237121310> ?p ?o ?g. }

• W4237121310 endingPage "477" @default.
• W4237121310 startingPage "477" @default.
• W4237121310 abstract "Abstract Purpose: Biliary tract cancer (BTC) is a devastating disease of the digestive system with poor prognosis. Targeted therapy based on specific genetic alterations has been proven to be an effective treatment for some cancer subtypes. However, the effect of this targeted therapy is unclear in BTC. In this study, we aimed to explore the clinical efficacy and safety of personalized targeted therapy guided by targeted deep sequencing for advanced biliary tract cancer (BTC) patients. Materials and Methods: In this retrospective study, targeted deep sequencing was employed for 49 patients with BTC and the recommendation of biologic agent was offered. Among 32 patients with stage IV and R2 resection, 21 patients underwent conventional chemotherapy (mGEMOX) (chemotherapy group), while the remaining 11 patients received a personalized targeted agent (targeted therapy group). The progression-free survival (PFS), overall survival (OS), disease control rate (DCR) were used to assess the efficacy of treatments, while the grade of treatment-related toxicities was evaluated for safety. Results: The genomic landscape of 49 patients with BTC was depicted by targeted deep sequencing. Further analysis of all alterations demonstrated that these altered genes were highly enriched in the ERBB family or cell cycle pathway. After a median follow-up of 12 months, the targeted therapy group had a significant prolonged PFS (4.5 months vs. 1.5 months, P = 0.014) and a trend of prolonged OS (12.9 months vs. 4.1 months, P = 0.104) in comparison to the chemotherapy group. The DCR in the targeted therapy group was marginally higher but without statistical significance (63.6% vs. 33.3%, P = 0.142). In addition, there was no statistically significant difference in the percentage of patients that experienced Grade &gt;2 treatment-related toxicities in either treatment group (36.4% vs 19.0%, P = 0.397). Conclusions: This real-world clinical study suggests that targeted deep sequencing contributes to guiding personalized targeted therapy based on individual actionable mutations, which may benefit advanced BTC patients. Large umbrella trials of personalized precision therapy are needed to further confirm the clinical efficacy and safety of this therapeutic strategy in BTC. Note: This abstract was not presented at the meeting. Citation Format: Feiling Feng, Qingbao Cheng, Dadong Zhang, Bin Li, Hao Qin, Chang Xu, Miao Han, Yong Yu, Zhizhen Li, Jing-Yu Li, Zhiquan Qiu, Lei Xiong, Chen Liu, Fugen Li, Bin Yi, Xiaoqing Jiang. Targeted deep sequencing contributes to guiding personalized targeted therapy in advanced biliary tract cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 477." @default.
• W4237121310 created "2022-05-12" @default.
• W4237121310 creator A5000885898 @default.
• W4237121310 creator A5001631757 @default.
• W4237121310 creator A5003360183 @default.
• W4237121310 creator A5013902519 @default.
• W4237121310 creator A5015379338 @default.
• W4237121310 creator A5029695887 @default.
• W4237121310 creator A5038385200 @default.
• W4237121310 creator A5038656616 @default.
• W4237121310 creator A5039193396 @default.
• W4237121310 creator A5042785211 @default.
• W4237121310 creator A5047459083 @default.
• W4237121310 creator A5056381675 @default.
• W4237121310 creator A5056774831 @default.
• W4237121310 creator A5057947122 @default.
• W4237121310 creator A5069340040 @default.
• W4237121310 creator A5085898704 @default.
• W4237121310 date "2019-07-01" @default.
• W4237121310 modified "2023-10-16" @default.
• W4237121310 title "Abstract 477: Targeted deep sequencing contributes to guiding personalized targeted therapy in advanced biliary tract cancer" @default.
• W4237121310 doi "https://doi.org/10.1158/1538-7445.am2019-477" @default.
• W4237121310 hasPublicationYear "2019" @default.
• W4237121310 type Work @default.
• W4237121310 citedByCount "0" @default.
• W4237121310 crossrefType "journal-article" @default.
• W4237121310 hasAuthorship W4237121310A5000885898 @default.
• W4237121310 hasAuthorship W4237121310A5001631757 @default.
• W4237121310 hasAuthorship W4237121310A5003360183 @default.
• W4237121310 hasAuthorship W4237121310A5013902519 @default.
• W4237121310 hasAuthorship W4237121310A5015379338 @default.
• W4237121310 hasAuthorship W4237121310A5029695887 @default.
• W4237121310 hasAuthorship W4237121310A5038385200 @default.
• W4237121310 hasAuthorship W4237121310A5038656616 @default.
• W4237121310 hasAuthorship W4237121310A5039193396 @default.
• W4237121310 hasAuthorship W4237121310A5042785211 @default.
• W4237121310 hasAuthorship W4237121310A5047459083 @default.
• W4237121310 hasAuthorship W4237121310A5056381675 @default.
• W4237121310 hasAuthorship W4237121310A5056774831 @default.
• W4237121310 hasAuthorship W4237121310A5057947122 @default.
• W4237121310 hasAuthorship W4237121310A5069340040 @default.
• W4237121310 hasAuthorship W4237121310A5085898704 @default.
• W4237121310 hasConcept C121608353 @default.
• W4237121310 hasConcept C126322002 @default.
• W4237121310 hasConcept C143998085 @default.
• W4237121310 hasConcept C2776694085 @default.
• W4237121310 hasConcept C2780258809 @default.
• W4237121310 hasConcept C2781230642 @default.
• W4237121310 hasConcept C3017919176 @default.
• W4237121310 hasConcept C32220436 @default.
• W4237121310 hasConcept C60644358 @default.
• W4237121310 hasConcept C71924100 @default.
• W4237121310 hasConcept C86803240 @default.
• W4237121310 hasConceptScore W4237121310C121608353 @default.
• W4237121310 hasConceptScore W4237121310C126322002 @default.
• W4237121310 hasConceptScore W4237121310C143998085 @default.
• W4237121310 hasConceptScore W4237121310C2776694085 @default.
• W4237121310 hasConceptScore W4237121310C2780258809 @default.
• W4237121310 hasConceptScore W4237121310C2781230642 @default.
• W4237121310 hasConceptScore W4237121310C3017919176 @default.
• W4237121310 hasConceptScore W4237121310C32220436 @default.
• W4237121310 hasConceptScore W4237121310C60644358 @default.
• W4237121310 hasConceptScore W4237121310C71924100 @default.
• W4237121310 hasConceptScore W4237121310C86803240 @default.
• W4237121310 hasIssue "13_Supplement" @default.
• W4237121310 hasLocation W42371213101 @default.
• W4237121310 hasOpenAccess W4237121310 @default.
• W4237121310 hasPrimaryLocation W42371213101 @default.
• W4237121310 hasRelatedWork W136880643 @default.
• W4237121310 hasRelatedWork W2044356208 @default.
• W4237121310 hasRelatedWork W2085367843 @default.
• W4237121310 hasRelatedWork W2316766300 @default.
• W4237121310 hasRelatedWork W2390837439 @default.
• W4237121310 hasRelatedWork W2409070295 @default.
• W4237121310 hasRelatedWork W2410844646 @default.
• W4237121310 hasRelatedWork W2887014156 @default.
• W4237121310 hasRelatedWork W338726724 @default.
• W4237121310 hasRelatedWork W4237121310 @default.
• W4237121310 hasVolume "79" @default.
• W4237121310 isParatext "false" @default.
• W4237121310 isRetracted "false" @default.
• W4237121310 workType "article" @default.